Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Topical GSK2894512 in Atopic Dermatitis
NCT02466152Phase 1Completed
- Sponsor
- GSK
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tapinarof in atopic dermatitis (AD) (2 cohorts), sponsored by GSK. Primary endpoints: Composite of pharmacokinetic parameters at Day 22, Number of subjects with adverse events and 3 more. Started May 2015; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02466152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466152.